Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
Anthropic had its Claude models design small proteins on their own that dock onto target structures in the body, a key step in early drug development. The hit rate reached up to 35 percent, far above the industry average of…
